This trial is evaluating whether GnRH analog will improve 1 primary outcome in patients with Prostate Cancer. Measurement will happen over the course of From the date of randomization to the date of progression, death from any cause or last known follow-up date, assessed up to 5 years..
This trial requires 242 total participants across 2 different treatment groups
This trial involves 2 different treatments. GnRH Analog is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
The cancer is not curable. The best results can sometimes be achieved by a combination of surgery, radiation, and watchful waiting. A curative treatment plan depends on the stage of the disease, the person's age, his/her preferences and general health status.
The treatments for prostate cancer are very diverse because of the complexity of its development. In addition to the known treatments and drugs, some treatments are still under investigation. While specific treatment of prostate cancer is difficult, our review describes the common treatment options in prostate cancer.
It is the second most common type of cancer worldwide occurring in the prostate gland and the inner organs. A cancer that can be deadly, it is only treatable when caught early and there are many screening tests available that help find the cancer early. Cancer of the prostate is the most common form of cancer worldwide in males. theme:
biogeography question: Is the biogeography of the plant family Proteaceae : The continent of Gondwana a haven for the family? answer: The Australian region retains one of the richest and densest native flora of the world and retains a much higher level than other continents at present and in the recent past, a stark contrast to the present cosmopolitan flora of neighbouring continents.
Although the clinical trial protocol is a major determinant of inclusion in a trials, there is no absolute determinant for study participation because treatment selection also depends largely on the individual patients' willingness to be included. The authors contend that clinical trials may be inappropriate for the patients older than 75 years who experience little benefit and considerable risk and those younger than 75 who have relatively minor symptoms and minimal impairment in functional status.
The presenting symptoms of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) are typically nonspecific. The most common symptoms of prostate cancer are difficulty urinating or inability to urinate, an irregularly shaped lump in the prostate, pain caused by prostate swelling or the spread of cancer to the lymph nodes, back pain, or bone pain. However symptoms of prostate cancer may occur in combination. The most common symptoms of prostate cancer are pain, difficulty talking and difficulty getting urinated. The signs of prostate cancer are also nonspecific. Symptoms may include pain, swelling, itchiness and an enlarged prostate gland. Other potential symptom, depending on their location, may include a lump, unusual discharge from the penis or pain near the penis.
There is much debate relating to the causes of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer). Current trends of incidence show a peak rate in adolescence, similar to that of many other cancers. It has been theorised that puberty and the physiological changes associated with increased sex hormones have a role. Other risk factors have been highlighted including exposures to UV-light, and occupational toxins, particularly dioxins in tobacco smoke, and in grain processing and pesticide spraying. However, the evidence supporting these theories is questionable; this is especially true for the role of UV-light. Exposure to cigarette smoking and cannabis are also associated with the onset of prostate cancer, although the evidence for the link is also disputed.
Between 1991 and 1999, there were an estimated 49.9 million new cases of prostate cancer in the U.S., with 47.1 percent diagnosed while alive. The prevalence of newly diagnosed prostate cancer is high: between 25 and 33 percent in men over 60 years of age in several population-based or university or academic institution-based studies of either a hospital based or a population-based setting. Although incidence is rising, the number of new cases has not increased at a rate consistent with the prevalence. The risk for prostate cancer is highest among men over 70 years of age, as well as among men in their 50s.
The 5-year survival rate for prostate cancer in our region is 71.6% (n=844) in a population-based survey, whereas the 5-year survival rate for prostate cancer in the United States was 75.6% in 2001. The differences may be due to the earlier detection and diagnosis of prostate cancer in the United States or the use of modern diagnostic methods.
Prostate cancer has a substantial risk and is a major cause of morbidity and mortality in men between the ages of 50 and 80. The most common risk factor for developing [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer) is age at prostate-specific antigen (PSA) examination.
GnRH analogs have demonstrated to be more effective than placebo for the treatment of prostate hyperplasia. Therefore, it seems to be prudent to introduce the use of GnRH analogs for the treatment of BPH patients.
Prostate cancer cell invasion occurs through two sequential steps of cell displacement and cell invasion. This process is fast but requires the presence of a suitable extracellular matrix and cell adhesion molecules. This is a very dynamic process, especially at very early stages of cell invasion.
Current guidelines and guidelines recommendations, based on current science on the molecular biology of prostate cancer, place a strong emphasis on curative intent, and treatment of patients with high-risk disease will continue to be a challenge during the foreseeable future. Treatment for prostate cancer must continue to address risks and benefits with reasonable caution, and consideration for quality of life.